{"id":"W3217353697","doi":"10.1016/s2352-3026(21)00311-2","title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Lenalidomide; Medicine; Follicular lymphoma; Obinutuzumab; Internal medicine; Rituximab; Oncology; Lymphoma; Cohort; Neutropenia; Tolerability; Brentuximab vedotin; Gastroenterology; Chemotherapy; Adverse effect; Multiple myeloma; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001824437,0.0002585184,0.001507545,0.00009224287,0.0000660467,0.00001446283,0.0001129078,0.0001062468,0.00004470263],"category_scores_gemma":[0.0002492362,0.0001461561,0.00006538376,0.0002852032,0.0001541291,0.00005813465,0.0001014513,0.0001156605,0.000007337809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000795779,"about_ca_system_score_gemma":0.0007502466,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004195524,"about_ca_topic_score_gemma":0.0006066536,"domain_scores_codex":[0.9980791,0.000313871,0.000485985,0.0004403467,0.0002975289,0.0003831641],"domain_scores_gemma":[0.9984608,0.0003745013,0.0002397385,0.0006745996,0.0001493579,0.0001010427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01639214,0.02115027,0.9487895,0.0002199988,0.0008882716,0.006088311,0.004063677,0.000009740443,0.0001005844,0.0001717457,0.0002042243,0.001921541],"study_design_scores_gemma":[0.2769307,0.006646669,0.7085392,0.0004606429,0.001230367,0.0008901538,0.002179395,0.0002450762,0.001944499,0.00003798203,0.0006139514,0.0002813347],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965975,0.001269497,0.0000042846,0.0003691165,0.00008585846,0.001409589,0.00002022835,0.00003215959,0.0002117785],"genre_scores_gemma":[0.9989675,0.00009030586,0.0003116385,0.0003236395,0.00003397329,0.0001206303,0.00005454354,0.00002918521,0.00006862725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2605385,"threshold_uncertainty_score":0.5960073,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02440419732320716,"score_gpt":0.2849671350911839,"score_spread":0.2605629377679768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}